• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
water filter
WATER FILTER FOR WATER PURIFIER
DUST BAG
Small dust filter
HUMIDIFIER FILTER
Oil fume adsorption filter

Novartis aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021

firstwordpharmaJune 23, 2021

Tag: Novartis , BioNTech , COVID-19 , Vaccine

Novartis aims to bottle more than 50 million doses of BioNTech’s COVID-19 vaccine this year at its fill-and-finish facility in Stein, Switzerland, as reported in KFGO.

Novartis aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021

The news comes after the European Union’s drug regulator approved the bottling plant.


Previous:Cyteir Therapeutics Announces Closing of Initial Public Offering

Next:Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Novartis aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021 | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

WHO-PQ Influenza Vaccine

WHO-PQ Influenza Vaccine
Influenza Vaccine(Split Virion),Inactivated with good efficacy

Influenza Vaccine(Split Virion),Inactivated with good efficacy
Good immunogenicity performance Influenza Vaccine (Split virion)

Good immunogenicity performance Influenza Vaccine (Split virion)
Hualan's Group ACYW135 Meningococcal Polysaccharide Vaccine

Hualan's Group ACYW135 Meningococcal Polysaccharide Vaccine
Hualan Influenza Vaccine

Hualan Influenza Vaccine
International standard Group ACYW135 Meningococcal Polysaccharide Vaccine with lower adverse effect

International standard Group ACYW135 Meningococcal Polysaccharide Vaccine with lower adverse effect
Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral

Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral
Hualan Biological H7N9 Inactivated Influenza Vaccine

Hualan Biological H7N9 Inactivated Influenza Vaccine
Vi Polysaccharide Typhoid Vaccine

Vi Polysaccharide Typhoid Vaccine
Quadrivalent Influenza Vaccine HUALAN

Quadrivalent Influenza Vaccine HUALAN

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service